ADDISON, Texas, Aug. 2 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) announced today that Altrazeal® Transforming Powder Dressing has been granted CE Mark Certification in all countries within the European Economic Area (“EEA”).
Commenting on the CE Mark Certification for Altrazeal®, ULURU President and CEO, Kerry P. Gray stated, “The issuance of a CE Mark for Altrazeal® represents a significant milestone for the commercial expansion of our advanced woundcare product. This prestigious CE Mark designation for Altrazeal® provides the Company with significant licensing and marketing opportunities throughout the EEA. In addition, the standards required to be met for granting a CE Mark are expected to also allow ULURU to more quickly gain approval for marketing this innovative product in Asia, South America, and other territories. CE marking is mandatory for advanced wound dressings and is the necessary approval for marketing in the EEA which consists of 27 Member States of the EU and EFTA countries.
With the granting of the CE Mark, the Company is evaluating potential collaborations to rapidly launch Altrazeal® in the first European market. Assuming the successful completion of a collaboration, Altrazeal® could potentially be launched in Europe prior to year end.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating the potential to complete a collaboration in Europe, the possibility of rapidly launching Altrazeal® in Europe prior to year end, the ability to more quickly gain marketing approvals in Asia, South America and other territories, and the success of our marketing and licensing efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.
